Overview

Nasal Decolonization of Dialysis Patients Noses

Status:
Enrolling by invitation

Trial end date:
2024-03-31

Target enrollment:
0

Participant gender:
All

Summary

Hemodialysis patients are at high-risk for infections, specifically Staphylococcus aureus infections. The investigators propose to 1) implement a novel intervention (nasal povidone-iodine at each hemodialysis session) to prevent S. aureus infections using a stepped-wedge cluster randomized trial, and 2) evaluate the feasibility and acceptability of this intervention. If successful, this intervention can be used among hemodialysis patients, and evaluated in other high-risk patient populations to prevent S. aureus infections.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Marin L. Schweizer, PhD

Collaborators:

3M
Agency for Healthcare Research and Quality (AHRQ)
Emory Healthcare
University of Illinois at Chicago
University of Pennsylvania
Washington University School of Medicine

Treatments:

Cadexomer iodine
Iodine
Povidone
Povidone-Iodine

Criteria

Inclusion Criteria:

- Adult patients receiving outpatient chronic hemodialysis at one of the 16 study
dialysis centers.

Note: the unit of randomization is the dialysis center, not the individual patient

Exclusion Criteria:

Patients receiving peritoneal dialysis or home hemodialysis Pregnant women Patients with
known sensitivity or allergy to iodine (documented or verbalized) Patients with active
bacterial infections Children < 18 years of age. Patients with infections at the beginning
of the study will enter the study after antibiotic treatment is complete.